DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effects of Subanesthetic Isoflurane/Sevoflurane in 60% Oxygen on Clinical In-vitro Experimental Sepsis

Information source: Fourth Military Medical University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Sepsis

Intervention: oxygen (Drug); Sevoflurane (Drug); Isoflurane (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Fourth Military Medical University

Official(s) and/or principal investigator(s):
Lichao Hou, M.D., Ph.D., Principal Investigator, Affiliation: Xijing Hospital, Fourth Military Medical University

Overall contact:
Lichao Hou, M.D., Ph.D., Email: hou2001@fmmu.edu.cn

Summary

Sepsis is a major cause of death in intensive care units. Despite the investigators improved understanding, which has reduced the risk of dying with sepsis, the number of people who die each year continues to increase due to an overall increase in the number of cases. In our previous study, the investigators have showed that 100% oxygen or 0. 5 minimum alveolar concentration (MAC) isoflurane/sevoflurane in 60% oxygen protect mouse macrophage cell line against in-vitro sepsis induced by lipopolysaccharide (LPS). In this study, the investigator hypothesized that treatment of 100% oxygen or 0. 5 MAC isoflurane/sevoflurane in 60% oxygen protected against clinical in-vitro models of sepsis induced by LPS or plasma from septic patients.

Clinical Details

Official title: In-vitro Experimental Study About Effects of Subanesthetic Isoflurane/Sevoflurane in 60% Oxygen on Clinical In-vitro Sepsis

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Subcellular location of Nuclear Factor-KAPPA B p65 subunit

Secondary outcome:

tumor necrosis factor-alpha

interleukin- 1 beta

interleukin 6

Detailed description: 100% oxygen or 0. 5 MAC isoflurane/sevoflurane in 60% oxygen would inhibit increases of tumor necrosis factor (TNF)-alpha, interleukin-1beta, interleukin-6 in the cell culture supernatant after stimulation of LPS or plasma from septic patients, and also inhibit the nuclear location of nuclear factor-kappa B p65 subunit.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Human PBMCs were only isolated from the adult patients without sepsis/SIRS/infectious

diseases.

- The plasma for induction of clinical in-vitro sepsis, was only isolated from adult

patients with sepsis. Exclusion Criteria:

- Patients who had been selected for other clinical trials in the 3 months before.

Locations and Contacts

Lichao Hou, M.D., Ph.D., Email: hou2001@fmmu.edu.cn

Department of Anesthesiology, Xijing Hospital, Fourth Military Medical University,, Xi'an, Shaanxi 710032, China; Recruiting
lichao Hou, Email: hou2001@fmmu.edu.cn
Additional Information

Starting date: June 2014
Last updated: July 6, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017